Clinical Trial Update: To Evaluate the Safety and Efficacy of Meplazumab in Treatment of Post-COVID-19 [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating the safety and efficacy of meplazumab for post-COVID-19 has completed. The document notes the trial status as COMPLETED.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Post-acute Sequelae of Sars-cov-2 Infection

Drugs mentioned

• Meplazumab (meplazumab)

Snippet

Sponsor: Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd | Conditions: Post-COVID-19 | Phase 3 | Status: COMPLETED